Status:
UNKNOWN
Association Between a Multi-Gene Panel and Renal Denervation Effectiveness in Patients With Hypertension
Lead Sponsor:
Geneticure, LLC
Conditions:
Hypertension
Eligibility:
All Genders
18-80 years
Brief Summary
The purpose of this study is to assess the effectiveness of a multi-gene panel to determine which subjects are likely to respond to renal denervation therapy with Medtronic's Symplicity Spyral™ multi-...
Detailed Description
The objective of this study is to assess if renal denervation (RDN) effectiveness using the Symplicity SpyralTM multi-electrode renal denervation system is associated with ranked genomic scoring from ...
Eligibility Criteria
Inclusion
- Individual is currently or has previously been enrolled in a Medtronic clinical study utilizing the Symplicity Spyral™ multi-electrode renal denervation system.
- Subject received Renal Denervation.
- Subject has met the primary efficacy endpoint for the Medtronic Symplicity Spyral study and which arm they were randomized to.
- Individual agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study.
Exclusion
- Unable to provide written, informed, consent
Key Trial Info
Start Date :
December 5 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04060641
Start Date
December 5 2019
End Date
September 30 2022
Last Update
February 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baylor Scott and White Health
Dallas, Texas, United States, 75246